MX9801093A - C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen. - Google Patents
C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen.Info
- Publication number
- MX9801093A MX9801093A MX9801093A MX9801093A MX9801093A MX 9801093 A MX9801093 A MX 9801093A MX 9801093 A MX9801093 A MX 9801093A MX 9801093 A MX9801093 A MX 9801093A MX 9801093 A MX9801093 A MX 9801093A
- Authority
- MX
- Mexico
- Prior art keywords
- overproduction
- collagen
- treatment
- disorders related
- proteinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Abstract
The present invention relates to the novel use of organic molecules capable of inhibiting C-proteinase activity in order to regulate, modulate and/or inhibit abnormal collagen formation.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US203895P | 1995-08-08 | 1995-08-08 | |
US002038 | 1995-08-08 | ||
US60120396A | 1996-02-14 | 1996-02-14 | |
US601203 | 1996-02-14 | ||
US60918796A | 1996-03-01 | 1996-03-01 | |
US609187 | 1996-03-01 | ||
PCT/US1996/012876 WO1997005865A1 (en) | 1995-08-08 | 1996-08-08 | C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen |
Publications (2)
Publication Number | Publication Date |
---|---|
MXPA98001093A MXPA98001093A (en) | 1998-04-01 |
MX9801093A true MX9801093A (en) | 1998-04-30 |
Family
ID=27357060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9801093A MX9801093A (en) | 1995-08-08 | 1996-08-08 | C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0845987A4 (en) |
JP (1) | JPH11511137A (en) |
KR (1) | KR19990036271A (en) |
CN (1) | CN1198096A (en) |
AU (1) | AU6951296A (en) |
BR (1) | BR9609883A (en) |
CA (1) | CA2229098A1 (en) |
MX (1) | MX9801093A (en) |
WO (1) | WO1997005865A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1997006242A1 (en) * | 1995-08-08 | 1997-02-20 | Thomas Jefferson University | Recombinant c-proteinase and processes, methods and uses thereof |
US5994351A (en) * | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
EP0939628B1 (en) * | 1996-07-22 | 2003-03-05 | Monsanto Company | Thiol sulfone metalloprotease inhibitors |
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
EA199900139A1 (en) * | 1996-08-23 | 1999-08-26 | Пфайзер, Инк. | DERIVATIVES OF ARYL SULPHONYLAMINO HYDROXAMIC ACID |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
GB9706255D0 (en) * | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
US6037139A (en) * | 1997-06-03 | 2000-03-14 | Wisconsin Alumni Research Foundation | System for assaying modulators of procollagen maturation |
PL338235A1 (en) | 1997-07-22 | 2000-10-09 | Shionogi & Co | Preparation for treating or preventing glomerulopathic states |
BR9810841A (en) * | 1997-07-31 | 2001-07-10 | Procter & Gamble | Alicyclic metalloprotease inhibitors |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
US6107291A (en) * | 1997-12-19 | 2000-08-22 | Amgen Inc. | Azepine or larger medium ring derivatives and methods of use |
US6107337A (en) * | 1998-08-06 | 2000-08-22 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
TR200101663T2 (en) | 1998-12-10 | 2001-11-21 | F.Hoffmann-La Roche Ag | Pro-collagen c-proteinase inhibitors |
US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
AU769319B2 (en) * | 1998-12-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Sulfonamide hydroxamates |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6506936B1 (en) * | 1999-02-25 | 2003-01-14 | Fibrogen, Inc. | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production |
BR0009244A (en) | 1999-03-03 | 2002-04-16 | Procter & Gamble | Diheter metalloprotease inhibitors replaced |
US6197770B1 (en) | 1999-03-03 | 2001-03-06 | The Procter & Gamble Co. | Alkenyl- and alkynl-containing metalloprotease inhibitors |
US6448278B2 (en) | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
US6462063B1 (en) | 2000-02-04 | 2002-10-08 | Fibrogen, Inc. | C-proteinase inhibitors |
US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
AU2003221786A1 (en) | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
DE60327432D1 (en) * | 2002-05-29 | 2009-06-10 | Merck & Co Inc | USEFUL COMPOUNDS FOR THE TREATMENT OF ANTHRAX AND INHIBITION OF THE LETAL FACTOR |
EP1572645A2 (en) | 2002-12-03 | 2005-09-14 | Enobia Pharma Inc. | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex |
CA2548442A1 (en) * | 2003-12-19 | 2005-07-07 | Basf Aktiengesellschaft | Benzoyl-substituted phenylalanine amides |
JP2007537256A (en) | 2004-05-11 | 2007-12-20 | メルク エンド カムパニー インコーポレーテッド | Process for the preparation of N-sulfonated amino acid derivatives |
US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
ES2531520T3 (en) | 2007-05-04 | 2015-03-16 | Marina Biotech, Inc. | Lipoamino acids and their uses |
WO2009097893A1 (en) * | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp |
JP7189369B2 (en) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | Compounds for inhibition of alpha4beta7 integrin |
KR102641718B1 (en) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
PE20211866A1 (en) | 2018-10-30 | 2021-09-21 | Gilead Sciences Inc | QUINOLINE DERIVATIVES AS INHIBITORS OF INTEGRIN ALFA4BETA7 |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
US4687841A (en) * | 1985-10-18 | 1987-08-18 | Monsanto Company | Peptide hydroxamic acid derivatives |
US4925868A (en) * | 1986-08-29 | 1990-05-15 | Takeda Chemical Industries, Ltd. | 4-Hydroxy-3-pyrrolin-2-ones and treatment of circulatory disorders therewith |
US5292926A (en) * | 1988-01-25 | 1994-03-08 | Santen Pharmaceutical Co., Ltd. | Cysteine derivatives |
FR2626882B1 (en) * | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | VINCA DERIVATIVE CONJUGATES COMPRISING A DETERGENT CHAIN IN POSITION C-3 |
NZ229004A (en) * | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
FR2655339B2 (en) * | 1989-04-19 | 1992-04-10 | Medgenix Group Sa | COMPOUNDS AND COMPLEXES USEFUL IN PARTICULAR IN MEDICAL IMAGING. |
GB9008078D0 (en) * | 1990-04-10 | 1990-06-06 | Beecham Group Plc | Novel compounds |
US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5114953A (en) * | 1990-11-21 | 1992-05-19 | University Of Florida | Treatment for tissue ulceration |
US5443815A (en) * | 1991-11-27 | 1995-08-22 | Diatech, Inc. | Technetium-99m labeled peptides for imaging |
US5256657A (en) * | 1991-08-19 | 1993-10-26 | Sterling Winthrop, Inc. | Succinamide derivative matrix-metalloprotease inhibitors |
US5237057A (en) * | 1992-04-06 | 1993-08-17 | Biosite Diagnostics, Inc. | Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5393902A (en) * | 1994-04-26 | 1995-02-28 | Lever Brothers Company, Division Of Conopco, Inc. | Process for the preparation of bis(amidocarboxylic acids) |
-
1996
- 1996-08-08 MX MX9801093A patent/MX9801093A/en unknown
- 1996-08-08 BR BR9609883A patent/BR9609883A/en not_active Application Discontinuation
- 1996-08-08 WO PCT/US1996/012876 patent/WO1997005865A1/en not_active Application Discontinuation
- 1996-08-08 JP JP9508648A patent/JPH11511137A/en active Pending
- 1996-08-08 CN CN96197271A patent/CN1198096A/en active Pending
- 1996-08-08 KR KR1019980700939A patent/KR19990036271A/en not_active Application Discontinuation
- 1996-08-08 CA CA002229098A patent/CA2229098A1/en not_active Abandoned
- 1996-08-08 AU AU69512/96A patent/AU6951296A/en not_active Abandoned
- 1996-08-08 EP EP96930499A patent/EP0845987A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR9609883A (en) | 1999-03-23 |
AU6951296A (en) | 1997-03-05 |
EP0845987A4 (en) | 2000-05-24 |
CN1198096A (en) | 1998-11-04 |
EP0845987A1 (en) | 1998-06-10 |
CA2229098A1 (en) | 1997-02-20 |
WO1997005865A1 (en) | 1997-02-20 |
KR19990036271A (en) | 1999-05-25 |
JPH11511137A (en) | 1999-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9801093A (en) | C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen. | |
MX9606401A (en) | Indolinone compounds for the treatment of disease. | |
DE69815090D1 (en) | USE OF CHOLINESTERASE INHIBITORS FOR TREATING CONCENTRATIONAL DISORDER | |
BG102738A (en) | Inhibitors of farnesyl-protein transferase | |
DE60015070D1 (en) | USE OF ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF THE HEADACHE CLUSTER | |
WO2000061167A3 (en) | TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS | |
DE59903921D1 (en) | INDOLDER DERIVATIVES AND THE USE THEREOF FOR TREATING MALIGNAS AND OTHER DISEASES BASED ON PATHOLOGICAL CELL PROLIFERATIONS | |
ATE321548T1 (en) | USE OF STATIN TO TREAT SKIN DISEASES | |
BG104780A (en) | Inhibitors of phospholipase enzymes | |
GB9323165D0 (en) | Compounds | |
DE60121808D1 (en) | USE OF A POLYPEPTIDE CONTAINING THE EXTRACELLULAR DOMAIN OF IL-20RA AND IL-20RB FOR THE TREATMENT OF INFLAMMATION | |
FR2706767B1 (en) | ||
ATE271865T1 (en) | USE OF CHOLINESTERASE INHIBITORS TO TREAT ATTENTION DEFICIENCY DISORDER | |
ATE214272T1 (en) | TOPICAL USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT EYE PAIN | |
ATE210447T1 (en) | USE OF CCK-B RECEPTOR ANTAGONISTS TO TREAT SLEEP DISORDERS | |
DE59209728D1 (en) | USE OF ANTAGONISTS OR PARTIAL AGONISTS ON THE 5-HT 1a RECEPTOR TO TREAT AND PREVENT COGNITIVE DISORDERS | |
AU2002248180A1 (en) | Non-apoptotic forms of cell death and methods of modulation | |
TR200101578T2 (en) | Process for tissue paper product and manufacturing | |
DE60220825D1 (en) | USE OF NOREPINEPHRINE RECEPTACLES FOR THE TREATMENT OF TICKS | |
DE69623767D1 (en) | USE OF PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF ALCOHOLISM | |
DE69701258T2 (en) | USE OF BENZONAPHTALENE DERIVATIVES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | |
ATE369143T1 (en) | USE OF NGALI NUT OIL TO TREAT/RELIEF ARTHRITIS PAIN AND OTHER SIMILAR DISORDERS | |
NZ512546A (en) | Use of actylcholine esterase inhibitors to treat delirium | |
HK1056120A1 (en) | Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder. | |
AU2003282035A1 (en) | Modulation of s6 kinase activity for the treatment of obestiy |